
Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France
Novo Nordisk today announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 20231 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases. The investment…











